Abiraterone acetate-associated QT prolongation and torsades de pointes: Postmarketing cases reported to FDA

被引：3

作者：

McBride, Lauren ^{[1
]}

Woronow, Daniel ^{[1
]}

Nayernama, Afrouz ^{[1
]}

Christopher Jones, S. ^{[1
]}

机构：

[1] US FDA, Div Pharmacovigilance, Off Surveillance & Epidemiol, Silver Spring, MD USA

来源：

JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2021年 / 27卷 / 05期

关键词：

D O I：

10.1177/10781552211015794

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1315 / 1316

页数：2

共 6 条

[1]

[Anonymous], 2020, ZYT AB AC PACK INS

[2]

[Anonymous], 2020, YONS AB AC PACK INS

[3] Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

Yap, Timothy A. ;

Raynaud, Florence ;

Dowsett, Mitch ;

Settatree, Sarah ;

Barrett, Mary ;

Parker, Christopher ;

Martins, Vanessa ;

Folkerd, Elizabeth ;

Clark, Jeremy ;

Cooper, Colin S. ;

Kaye, Stan B. ;

Dearnaley, David ;

Lee, Gloria ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571

[4]

Center for Drug Evaluation and Research, 2011, PHARM REV NDA 202379

[5]

Khan A, 2016, NEW ZEAL MED J, V129, P124

[6] Abiraterone Acetate-Induced Life-Threatening Torsade de Pointes [J].

Rodieux, Frederique ;

Nieto, Nathalie ;

Sunthorn, Henri ;

John, Gregor ;

Escher, Monica .

ANNALS OF PHARMACOTHERAPY, 2015, 49 (01) :152-153

← 1 →